drugset
drugset / Trial / NCT05515445

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT05515445 ↗

Phase 1 Completed 24 enrolled Chipscreen Biosciences, Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.

Timeline

Start
2022-12-03
Primary completion
2023-08-23
Completion
2023-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Chiglitazar Unknown 48 mg Oral

Indications

No indication recorded.